Comments on: Limitations of HPV DNA Testing in Screening of Cervical Adenocarcinomas

Dear Editor,

I read with great interest the article on HPV DNA testing for cervical cancer screening in Brazil, authored by the Brazilian Association for the Lower Genital Tract Pathology and Colposcopy (ABPTGIC, in the Portuguese acronym).[1] In agreement with the authors, I have found irrefutable evidence sustaining the use of molecular detection of HPV DNA in this setting. However, every method, no matter how innovative or advanced, has limitations. The “Achilles' heel” of HPV DNA primary screening is the detection of glandular lesions. I found that the manuscript by the ABPTGIC tangentially addressed this issue.

An international cross-sectional study found that 38% of adenocarcinomas were not HPV-related.[2] A recently proposed histologic classification of endocervical adenocarcinoma, known as International Endocervical Adenocarcinoma Criteria and Classification (IECC),[3] uses the presence of HPV-related disease to histologically classify cervical adenocarcinomas. Among nonhuman papillomavirus-associated adenocarcinoma (NHPVA), the authors identify the following histological types: endometrial, gastric-type, minimal deviation, serous, clear-cell and mesonephric. In our practice, we have recently been involved in the case of an asymptomatic woman, HPV DNA-negative, who showed abnormal cytologic results interpreted as high-grade lesion. The patient proved to have a cervical clear-cell adenocarcinoma. This tumor is classified by the IECC group as a NHPVA and would not be identified in the screening scenario by molecular assays based on HPV DNA.

In summary, it is well recognized that HPV DNA detection delivers high sensibility, which is of great help, since cytologic-based screening is known to have low sensibility and high false-negative rates.[4] [5] But the limitations of this molecular detection should be recognized, such as the great proportion of NHPVAs. If molecular testing for HPV DNA is to be used as a primary screening test, one must acknowledge that non-HPV-related tumors would be missed.

• References

• 1 Zeferino LC, Bastos JB, Vale DBAPD. , et al. Guidelines for HPV-DNA testing for cervical cancer screening in Brazil. Rev Bras Ginecol Obstet 2018; 40 (06) 360-368 Doi: 10.1055/s-0038-1657754
• 2 de Sanjose S, Quint WG, Alemany L. , et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11) 1048-1056 Doi: 10.1016/S1470-2045(10)70230-8
• 3 Stolnicu S, Barsan I, Hoang L. , et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol 2018; 42 (02) 214-226 Doi: 10.1097/PAS.0000000000000986
• 4 Nanda K, McCrory DC, Myers ER. , et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000; 132 (10) 810-819 Doi: 10.7326/0003-4819-132-10-200005160-00009
• 5 Cuzick J, Clavel C, Petry KU. , et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006; 119 (05) 1095-1101

• References

• 1 de Sanjose S, Quint WG, Alemany L. , et al; Retrospective International Survey and HPV Time Trends Study Group. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010; 11 (11) 1048-1056 Doi: 10.1016/S1470-2045(10)70230-8
• 2 Bucchi L, Baldacchini F, Mancini S. , et al. Estimating the impact of an organised screening programme on cervical cancer incidence: a 26-year study from northern Italy. Int J Cancer 2018 •••;. Doi: 10.1002/ijc.31806
• 3 Stolnicu S, Barsan I, Hoang L. , et al. International Endocervical Adenocarcinoma Criteria and Classification (IECC): a new pathogenetic classification for invasive adenocarcinomas of the endocervix. Am J Surg Pathol 2018; 42 (02) 214-226 Doi: 10.1097/PAS.0000000000000986
• 4 Ronco G, Dillner J, Elfström KM. , et al; International HPV screening working group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014; 383 (9916): 524-532 Doi: 10.1016/S0140-6736(13)62218-7
• 5 Andrae B, Kemetli L, Sparén P. , et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst 2008; 100 (09) 622-629 Doi: 10.1093/jnci/djn099